This Article Full Text Full Text (PDF) Supplementary Data All Versions of this Article: 0008-5472.CAN-08-4490v1 69/17/6871    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Liu, L. Articles by Gilmer, T. M. PubMed PubMed Citation Articles by Liu, L. Articles by Gilmer, T. M.

Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL

Departments of ¹ Translational Research and ² Proteomics and Biological Mass Spectrometry Laboratory, GlaxoSmithKline, King of Prussia, Pennsylvania; Departments of ³ Biomarkers, ⁴ Cancer Metabolism DPU, Cancer Research, and ⁵ Molecular and Cellular Technologies, GlaxoSmithKline, Collegeville, Pennsylvania; and ⁶ Department of Translational Research, GlaxoSmithKline, Research Triangle Park, North Carolina

Requests for reprints: Tona M. Gilmer, GlaxoSmithKline, 5.5806, Research Triangle Park, NC 27709-3398. Phone: 919-483-6335; Fax: 919-315-3749; E-mail: tona.m.gilmer{at}gsk.com.

Key Words: HER2 breast cancer • AXL • lapatinib • trastuzumab

HER2-directed therapies, such as trastuzumab and lapatinib, are important treatments for breast cancer. However, some tumors do not respond or develop resistance to these agents. We isolated and characterized multiple lapatinib-resistant, HER2-positive, estrogen receptor (ER)–positive breast cancer clones derived from lapatinib-sensitive BT474 cells by chronic exposure to lapatinib. We show overexpression of AXL as a novel mechanism of acquired resistance to HER2-targeted agents in these models. GSK1363089 (foretinib), a multikinase inhibitor of AXL, MET, and vascular endothelial growth factor receptor currently in phase II clinical trials, restores lapatinib and trastuzumab sensitivity in these resistant cells that exhibit increased AXL expression. Furthermore, small interfering RNA to AXL, estrogen deprivation, or fulvestrant, an ER antagonist, decreases AXL expression and restores sensitivity to lapatinib in these cells. Taken together, these data provide scientific evidence to assess the expression of AXL in HER2-positive, ER-positive patients who have progressed on either lapatinib or trastuzumab and to test the combination of HER2-targeted agents and GSK1363089 in the clinic. [Cancer Res 2009;69(17):6871–8]